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Key Points
• Induced miR-155
expression promotes
vincristine sensitivity in
DLBCL cell lines.
•High miR-155 expres-
sion is associated with
superior clinical out-
come in patients with
DLBCL of the GCB
subclass.
A major clinical challenge of diffuse large B-cell lymphoma (DLBCL) is that up to 40% of
patients have refractory disease or relapse after initial response to therapy as a result of
drug-specific molecular resistance. The purpose of the present study was to investigate
microRNA (miRNA) involvement in vincristine resistance in DLBCL, which was pursued by
functional in vitro analysis in DLBCL cell lines and by outcome analysis of patients with
DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and predni-
sone (R-CHOP). Differential miRNA expression analysis identified miR-155 as highly
expressed in vincristine-sensitive DLBCL cell lines compared with resistant ones. Ectopic
upregulation of miR-155 sensitized germinal-center B-cell-like (GCB)–DLBCL cell lines to
vincristine, and consistently, reduction and knockout of miR-155 induced vincristine
resistance, documenting that miR-155 functionally induces vincristine sensitivity. Target
gene analysis identified miR-155 as inversely correlated with Wee1, supporting Wee1
as a target of miR-155 in DLBCL. Chemical inhibition of Wee1 sensitized GCB cells to
vincristine, suggesting that miR-155 controls vincristine response through Wee1.
Outcome analysis in clinical cohorts of DLBCL revealed that high miR-155 expression
level was significantly associated with superior survival for R-CHOP-treated patients of
the GCB subclass, independent of international prognostic index, challenging the commonly
accepted perception of miR-155 as an oncomiR. However, miR-155 did not provide
prognostic information when analyzing the entire DLBCL cohort or activated B-cell–like
classified patients. In conclusion, we experimentally confirmed a direct link between
high miR-155 expression and vincristine sensitivity in DLBCL and documented an
improved clinical outcome of GCB-classified patients with high miR-155 expression level.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most frequent type of non-Hodgkin’s lymphoma, characterized
by great heterogeneity regarding clinical presentation, tumor biology, and prognosis.1 Gene expression
profiling (GEP) defines cell-of-origin subtypes reflecting normal B-cell differentiation stages and permits
classification of DLBCL into activated B-cell-like (ABC) and germinal-center B-cell–like (GCB), which
differ in pathogenic activation mechanisms, genetic aberrations, and clinical outcome.2,3 Although this
classification has expanded our biological understanding of DLBCL, molecular mechanisms related
to treatment response and resistance are still not fully understood.
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The addition of rituximab (R) to the multiagent chemotherapy
regimen cyclophosphamide, doxorubicin, vincristine, and predniso-
lone (CHOP) has increased DLBCL survival substantially; however,
30% to 40% of patients ultimately die of relapse or refractory
disease because of treatment resistance.4-6 As a consequence,
novel treatments and predictive biomarkers are urgently war-
ranted, and equally important, improved biological understanding
is required for mechanisms leading to resistance. Several clinical
trials have aimed at improving the R-CHOP regimen by dose
adjustments, cycles, or add-on drugs, but with limited benefit,
emphasizing that increased knowledge of R-CHOP resistance is
still highly relevant.7-9 The antimitotic drug vincristine has been used
as anticancer therapy for more than 40 years and is a cornerstone for
efficacy of R-CHOP because of its broad cytotoxic effect, limited
bone marrow suppression, and high tolerability.10,11 Despite wide
use of vincristine, little is known about determinants of vincristine
resistance in treatment of DLBCL, a caveat when attempting to
improve clinical outcome.
Recent studies demonstrate that noncoding RNAs, and in particular
microRNAs (miRNAs), play important roles in the pathogenesis of
DLBCL.12-14 miRNAs regulate gene expression by targeting mRNA
for translational repression or degradation and are involved in cardinal
physiologic and pathologic processes.15 Aberrant miRNA expres-
sion is a common feature of malignancies and has been linked
to chemotherapy resistance.16-18 One of the most extensively
studied miRNAs in normal B-cell differentiation and hematolog-
ical cancers is miR-155,19,20 which acts as an oncomiR in the
pathogenesis and aggressiveness of DLBCL.21 In line, miR-155
levels in patients with ABC are significantly higher compared with
those detected in patients classified as having GCB,19 and transgenic
mice overexpressing miR-155 spontaneously develop DLBCL,22
emphasizing its importance in lymphomagenesis.
Early detection of drug-specific resistance is of pivotal importance
to successful cancer therapy, and defining miRNA involvement
could provide information on resistance mechanisms of the drug
and make miRNAs themselves biomarkers and treatment targets.
Because vincristine is a cornerstone in the treatment of DLBCL,
we studied the involvement of miRNAs in the response to this
antimitotic drug. To pinpoint miRNAs controlling vincristine response,
13 DLBCL cell lines were subjected to systematic dose-response
experiments and grouped as resistant, intermediate, or sensitive.23
Global miRNA expression profiling of these cell lines in untreated
condition was performed and miRNAs differentially expressed
between vincristine sensitive and resistant cell lines were identified,
showing miR-155 to be highly expressed in vincristine-sensitive cells.
Hence, experimental manipulations of miR-155 expression using
lentiviral gene delivery in DLBCL cells were performed to determine the
functional effect of miR-155 in vincristine response, and subsequently
a prognostic value of miR-155 was documented in 2 independent
R-CHOP-treated DLBCL cohorts.
Materials and methods
Cell lines
DLBCL cell lines (supplemental Table 1) were cultured at 37°C in
a humidified atmosphere of 95% air and 5% CO2 with RPMI1640
medium, 10% fetal bovine serum, and 1% penicillin/streptomycin.
HEK293T cells were maintained in Dulbecco’s modified Eagle medium
containing 5% fetal bovine serum and 1% penicillin/streptomycin.
All cell lines were authenticated by DNA barcoding23 and examined
for mycoplasma infection.
Clinical samples
Diagnostic biopsies from 73 patients with DLBCL (supplemental
Table 2) were collected in agreement with the RetroGen research
protocol and reviewed and approved by the health ethic committee of
the North Denmark Region (approval jr. no. N-20140099), allowing
exemption from the Declaration of Helsinki requirement of informed
consent according to sections 3 to 5 in the Danish Act on Research
Ethics Review of Health Research Projects. Informed consent was
waived, as this notifiable database research project did not involve
any health risks and, under the given conditions, could not otherwise
put a strain on the trial subject. In addition, it would be impossible or
disproportionately difficult to obtain informed consent or proxy consent,
respectively, because of the use of archival samples and because
several patients have died since collection. Of the 73 patients with
DLBCL, 69 were treated with standard R-CHOP. In addition, we used
Gene Expression Omnibus data (GSE1084624 and GSE313123).
Dose-response assays
Vincristine dose-response screens were performed on DLBCL cell
lines, as previously described.23,25 Each cell line was subjected to 18
increasing concentrations for 48 hours, and dose-responses were
evaluated using a 3-(4,5 dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl-
2-(4-sulfophenyl)-2H-tetrazolium assay.
RNA extraction
RNAwas extracted using a protocol combining TRIzol (Invitrogen) and
mirVana miRNA Isolation Kit (Ambion/ThermoFisher Scientific)26 or
a RNAqueous Micro scale RNA Isolation kit (,500 000 cells;
ThermoFisher Scientific). RNA integrity and concentration were
determined using an Agilent 2100 Bioanalyzer and NanoDrop
ND-1000 spectrophotometer, respectively.
Microarray profiling
miRNA expression profiling was performed using GeneChip miRNA
1.0.2 arrays (Affymetrix), as previously described,17 and CEL files
are deposited at Gene Expression Omnibus (GSE72648). GEP of
clinical samples and transduced SU-DHL-5 cells was performed using
AffymetrixGeneChipHG-U133Plus2.0 arrays.CEL fileswere generated
using the Affymetrix Gene-Chip Command Console Software and de-
posited at Gene Expression Omnibus (GSE109027). Data comply
withMinimum Information About aMicroarray Experiment requirements.
Reverse transcription quantitative polymerase
chain reaction
miR-155 expression was determined by TaqMan miRNA reverse
transcription quantitative polymerase chain reaction (RT-qPCR;
Thermo Fisher Scientific). Two independent cDNA syntheses
were conducted and pooled before amplification qPCR analysis
(hsa-miR-155 [002623], RNU6B [001093], RNU24 [001001]).
Each sample was analyzed in triplicate, using Mx3000P (Stratagene/
Agilent Technologies). miRNA expression was normalized to RNU6B
and RNU24 and log2 transformed.
Plasmid construction
A lentiviral vector containing multiple cloning sites for insertion of PCR-
amplified miRNA sequences was generated.27,28 The sequence
1186 DUE et al 9 APRIL 2019 x VOLUME 3, NUMBER 7
.For personal use onlyon August 23, 2019. by guest  www.bloodadvances.orgFrom 
encoding pri-miR-155 was amplified from HeLa cells, using primers
59-AAAGCGGCCGCCATCTTTTAATTGCCAATTTCTCTACC-39
and 59-AAAGCGGCCGCGTTTAAGGTTGAACATCCCAGT-
GACC-39. Fragments were NotI-digested and inserted into Bsp120I
digested plasmid from corynebacterium callunae (pCCL) with a mul-
tiple cloning site (MCS) immediately downstream of the H1 promoter
(H1) and phosphoglycerate kinase promotor (PGK) controlling en-
hanced green fluorescent protein (eGFP) (pCCL/H1-MCS-PGK-
eGFP). For miR-155 inhibition, a Tough Decoy (TuD)–expressing
construct with high miRNA-suppressive capacity was generated by a
2-step cloning strategy.29,30 DNA sequences containing inhibitor
sequence flanked by NheI/AscI sites were synthesized and cloned
into pUC57 by GeneScript. Inhibitor sequences were cleaved from
pUC57 and cloned into AvrII/AscI-digested pCCL/PGK-eGFP.H1-MCS.
Sequences including TuD were PCR-amplified from lentiviral vectors
encoding H1 driven inhibitor, using 59-AAAAGGTACCGTATGAG-
ACCACCCTAGCCC-39 and 59-AAAAGGTACCCAGAGAGACC-
CAGTACAAGC-39. KpnI-digested PCR products were cloned into
KpnI-digested pCCL/PGK-eGFP.
To test functionality, sense and antisense oligonucleotides harbor-
ing miR-155 target sequence were annealed and cloned into
NotI/XhoI-digested psiCHECK-2 vector (Promega).29 Co-transfections
of HEK293T cells were performed with 7 ng pCCL/U1-miRNA.
PGK-eGFP, 14ng psiCHECK-miRtarget ,and 80 ng pCCL/
PGK-eGFP-TuD, using X-tremeGENE 9 (Roche). Renilla and
Firefly luciferase expression levels were measured 48 hours
posttransfection, using Dual-Glo Luciferase Reporter Assay Sys-
tem (Promega). Renilla luciferase activity was normalized to Firefly
and presented relative to negative control (pCCL/PGK-eGFP).
All plasmids were verified by sequencing (GATC; Konstanz, Germany).
Lentivirus production and transduction
To generate lentiviral vectors, 1 3 107 HEK293T cells were seeded in
25 mL Dulbecco’s modified Eagle medium. Twenty-four hours after
seeding, cells were transfected with 9.07 mg pMD.2G, 7.26 mg pRSV-
Rev, 31.46 mg pMDIg/p-RRE, and 31.46 mg lentiviral transfer vector.
Both 48 and 72 hours posttransfection, viral supernatant was harvested,
filtered (0.45 mm), and ultracentrifuged. Virus yield was determined by
measurements of p24 capsid protein, using p24 Antigen ELISA
Kit (XpressBio). DLBCL cells were seeded at 300 000 cells/mL
in 1 mL standard RPMI and transduced with virus corresponding
to 85 ng p24. DLBCL cell lines SU-DHL-5, OCI-Ly7, NU-DHL-1,
and RIVA were selected on the basis of ABC/GCB classification,
resistance/sensitivity to vincristine, and lentiviral transducibility.27
RT-qPCR was used to confirm changes in miR-155 expression.
CRISPR-Cas9 knockout
Single guide RNA (sgRNA) was designed to target the functional part
of MIR155HG (supplemental Figure 1). Sense and antisense oligo-
nucleotides encoding the sgRNA were annealed and cloned into
pLV/CRISRP-v2, using BsmbI site.31 OCI-Ly7 was transduced
with LV/CRISPR-sgRNA-miR-155 or LV/CRISPR-sgRNA-control, the
latter without target in the human genome (59-ACGGAGGCTAAGC-
GTCGCAA-39) and subjected to puromycin selection (0.5 mg/mL).
After 2 weeks, gDNA was extracted using standard NaCl/EtOH
precipitation protocol, and gDNAencompassing theCas9 cut sites was
amplified using 59-AACTCCGAAGAGCGGTT-39 and 59-GGTTGA-
ACATCCCAGTGACC-39. Indel frequencies were determined by
sequence-based Tracking of Indels by Decomposition analysis.32
miR-155 knockout clones from single-cell expansion were gener-
ated by seeding 96-well plates at concentrations of 0.5 cell/well in
50 mL standard RPMI, 100 mL conditioned medium, and 50 mL
RPMI containing 55% fetal bovine serum and 3% penicillin/
streptomycin. Tracking of Indels by Decomposition analysis and
RT-qPCR was performed in individual clones.
Dose-response screen of transduced cells
Transduced cells and miR-155 knockout clones were seeded at
3 3 105 cells/mL in 1 mL standard RPMI. Cells were exposed to
vincristine for 48 hours, and viable cells were counted using trypan
blue exclusion. Transduced cells were treated with 2 concentra-
tions of vincristine (0.0005-0.001 mg/mL), whereas miR-155
knockout cells were exposed to 0.0005, 0.001, and 0.0015 mg/mL.
Transductions and functional assays were performed in triplicate in
2 independent assays.
Western blot
Cell lysates were prepared using RIPA Lysis Buffer supplemented
with complete miniprotease inhibitors, and protein concentration
was determined using BCA Pierce (Thermo Fisher Scientific).
Western blotting analysis was performed following standard Bio-
Rad procedures loading 20 mg total protein. Antibodies used were
b-actin (1:10 000, Abcam, ab6276), Wee1 (1:1,000, Santa Cruz
Biotechnology, sc-5285), Ship-1 (1:1000, Santa Cruz Biotech-
nology, sc-8425), and rabbit-anti-mouse IgG (1:10 000, Abcam,
ab6728).
Double drug analysis
Wee1 inhibitor MK-1775 (Selleck chemical) was dissolved in dimethyl
sulfoxide. OCI-Ly7 cells were seeded in 96-well plates at a density
of 0.25 3 106 cells/mL, 24 hours before drug was added. Cells
were exposed to 0.0015 mg/mL vincristine, 400 nM MK-1775, or
0.0015 mg/mL vincristine and 400 nM MK-1775 for 48 hours, and
metabolically active cells were determined by 3-(4,5 dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl-2-(4-sulfophenyl)-2H-tetrazolium-
containing CellTiter 96 Reagent at a concentration of 20% of
pre-additional well content. Absorbance was measured at 492 nm
(BMG, LABTECH).
Statistical analysis
Statistical analyses were performed with R (v.3.3.3).33 Array-based
miRNA and gene expression data were cohort-wise background
corrected and normalized at the probe and gene level, applying a
Robust Multichip Average approach,34 respectively.
Differential miRNA expression analysis was performed using the
limma Bioconductor package (v.3.26.9),35 setting P , .05 and
FC . |2| as the significance threshold.
To increase statistical power, external R-CHOP restricted cohorts3,24
were combined into a meta-cohort. The meta-cohort was batch
corrected using ComBat implemented in the sva Bioconductor
package (v.3.18.0),36,37 and miR-155 expression was quantified
through the MIR155HG probe set 229437_at included in HG-U133
Plus2.0 GeneChip. Validity of array-based quantification was
confirmed through correlation analysis, with RT-qPCR quantified
miR-155 expression in the in-house cohort.
Confounding effects of ABC/GCB subclasses and Cheson response
evaluation on miR-155 expression were investigated through simple
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linear regression analysis. Survival analyses were performed using
Kaplan-Meier and log-rank test statistics for progression-free survival
(PFS) and overall survival (OS). Furthermore, simple and multiple Cox
proportional hazards regression analyses were conducted using an
additive model with international prognostic index, ABC/GCB, and
miR-155 expression (dichotomized by median split into low and
high or as a continuous variable) as independent confounders.
Linear regression and survival analyses were conducted for all
patients with DLBCL and restricted to ABC and GCB classified
patients, respectively.
Gene set enrichment analysis (GSEA) was performed for trans-
duced cells (miR-155 vs control and TuD-155 vs control), using
the GSEA desktop application (v.3.0)38 with preranked gene lists,
2000 permutations of gene set randomization, and default settings
otherwise. GSEA was restricted to gene sets included in the
Hallmark collection from the Molecular Signatures Database
(v.6.0),38,39 excluding sets with fewer than 15 or more than
500 genes. Gene sets with normalized P # .05 and FDR
q # 0.25 were considered significantly enriched.
If not mentioned otherwise, 2-sided Student t tests were performed
to evaluate statistical significance, and significance thresholds were
set to 0.05.
Results
Identification of vincristine response-specific miRNAs
DLBCL cell lines subjected to vincristine dose-response screens
were ranked according to their sensitivity, using area under the
dose-response curve, and trichotomized into groups of sensitive,
intermediate, and resistant cells (supplemental Table 1).23,25 To
identify miRNAs associated with vincristine response, global miRNA
profiling was conducted for each cell line in untreated condition,
and subsequent differential miRNA expression analysis between
vincristine-sensitive and vincristine-resistant cell lines identified 15
differentially expressedmiRNAs (supplemental Table 3). LowmiR-155
expression displayed the strongest association to vincristine resis-
tance and was selected for further analyses (supplemental Figure 2).
Of notice, miR-155was the top candidate irrespective of split strategy
used to categorize cell lines as sensitive and resistant (4 sensitive,
5 intermediate, and 4 resistant; 6 sensitive and 7 resistant; data
not shown).
Downregulation of miR-155 promotes
vincristine resistance
To substantiate involvement of miR-155 in vincristine response,
lentiviral vectors encoding pri-miR-155 or TuD-155 for stable up-
and downregulation, respectively, were designed (Figure 1A).
Two GCB-DLBCL cell lines, SU-DHL-5 and OCI-Ly7, that are
intrinsically sensitive and resistant, respectively, to vincristine with
high and low levels of endogenous miR-155 (supplemental Table 1)
were transduced. Forty-eight hours posttransduction, the expres-
sion level of miR-155 was significantly increased by lentiviral vectors
encoding pri-miR-155 and reduced by TuD-155 (Figure 1BI-EI).
Ectopic expression of miR-155 did not have toxic effects because
total cell number was unchanged (supplemental Figure 3). More-
over, GSEA conducted for transcriptional profiles of transduced
SU-DHL-5 cells revealed that top enriched gene sets detected in
miR-155 overexpressing cells compared with controls were
associated with G2/M checkpoints and mitotic spindle assembly.
Consistently, those gene sets were enriched in control samples
when compared with cells with miR-155 knock-down (supplemental
Tables 4 and 5; supplemental Figure 4). Based on the antimitotic
effect of vincristine, those results suggest that miR-155 and
vincristine affect comparable biological processes.
Induction of miR-155 significantly increased vincristine sensitivity
in both GCB cell lines, and decreased miR-155 expression
consistently caused vincristine resistance in intrinsic vincristine-
sensitive SU-DHL-5 cells, whereas no change in response was
observed in the vincristine-resistant cell line OCI-Ly7 (Figure 1Bii-Eii).
Because downregulation of miR-155 did not affect vincristine
response in OCI-Ly7, 2 miR-155 knockout clones were generated
(supplemental Figure 5; Figure 2B). As a result of miR-155 depletion,
cell viability decreased, whereas no difference between vector
control and the parental wild-type counterpart was observed
(Figure 2A). Furthermore, miR-155 knockout increased vincristine
resistance over a range of concentrations (Figure 2C), indicating
that miR-155 functionally affected vincristine response in DLBCL
cells of the GCB subclass.
In addition, ABC cell lines RIVA and NU-DHL-1, characterized by
intrinsically intermediate response to vincristine and comparably
high endogenous expression of miR-155 (supplemental Table 1),
were similarly analyzed. Applying the TuD model system de-
creased miR-155 expression in RIVA cells; however, it did not
cause unambiguous effect on vincristine sensitivity (supplemental
Figure 6BI-BII). Although functionality of the model systems was
confirmed (supplemental Figure 7),28 transduction with LV/miR-155
in RIVA and LV/TuD-155 in NU-DHL-1 did not generate significant
changes in intracellular levels of miR-155, and consequently,
vincristine dose-response analysis was not performed (supple-
mental Figure 6AI,DI). Overexpression of miR-155 in NU-DHL-1 cells
did not affect vincristine response either (supplemental Figure 6CI-CII),
indicating that miR-155 does not play a pivotal role in vincristine
response in ABC cells as opposed to GCB cells.
The cell-cycle checkpoint geneWEE1 is a direct target
of miR-155
To identify target genes of miR-155 with an effect on vincristine
response, transcriptional profiles of ectopic miR-155 expressing
SU-DHL-5 cells were analyzed. On the basis of the antimitotic
effect of vincristine, resistance mechanisms could be related to
cell cycle processes, and thus negatively correlated genes associ-
ated with gene ontologies of cell cycle processes were selected
(n 5 64; supplemental Table 6).
To investigate whether selected genes were potential miR-155
targets, miR-155-mRNA interaction was investigated using well-
documented miRNA prediction algorithms (TargetScan, miRDB,
microT-CDC, and microRNA.org) and TarBase, a database of
experimentally validated miRNA-mRNA interactions. Only 1 gene,
WEE1, was predicted as a putative miR-155 target by all algorithms,
and was found as experimentally verified in TarBase. Notably, the
miR-155 binding site ofWEE1 is actively recognized by miR-155 in
luciferase-based reporter assays,40,41 and in agreement, induced
protein level of Wee1 was observed in miR-155 knockout clones
(Figure 2D-E). WEE1 encodes a kinase controlling G2/M phase
by inhibitory phosphorylation of Cdk1, through which Wee1 also
affects sensitivity to antimicrotubule drugs.42 In accordance,
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Figure 1. Changes in miR-155 expression in GCB-DLBCL
cell lines affect vincristine response. (A) Schematic
overview of lentiviral vector plasmids used as control (i), for
expression of miR-155 (ii) and TuD-155 (iii) inhibitor in fusion
with eGFP. (B-E) Up- and downregulation of miR-155 was
detected by RT-qPCR in (Bi,Ci) SU-DHL-5 and (Di,Ei)
OCI-Ly7 cells and followed by vincristine dose-response
analysis. (Bii,Cii,Dii,Eii) Drug response is illustrated
as percentage of living cells related to the no-drug
treated condition. CMV, cytomegalovirus promoter;
LTR, long terminal repeat; NQ, normalized quantity; PGK,
phosphoglycerate kinase promoter; WPRE, woodchuck
hepatitis virus posttranscriptional regulatory element.
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chemical inhibition of Wee1 in wild-type OCI-Ly7 cells decreased
the number of living cells and enhanced killing when given in
combination with vincristine (Figure 2F).
Prognostic effect of miR-155 expression in
GCB-DLBCL
The relationship between miR-155 expression and ABC/GCB
subclasses was examined in the in-house cohort, for which miR-155
expression was assayed by RT-qPCR. Higher expression of
miR-155 was observed in the ABC subclass (supplemental Figure 8),
in accordance with previous observations.19
To investigate the prognostic value of miR-155, dichotomized
miR-155 expression was analyzed for association with OS and
PFS in R-CHOP-treated patients. Because miR-155 is differ-
entially expressed between patients with ABC and GCB-DLBCL,
which display different pathogenesis and prognosis, survival analysis
was performed both overall and according to ABC and GCB
subclasses. A tendency for association between miR-155 and OS
and PFS was observed in the entire DLBCL cohort and for GCB-
classified patients, with low miR-155 expression characterizing
poor outcome (Figure 3; supplemental Figure 9).
To verify this trend, we investigated the prognostic value in an
independent meta-cohort of 701 patients with DLBCL, in which
miR-155 expression was quantified through the precursor MIR155HG.
In the in-house cohort, mature miR-155 expression measured
by RT-qPCR was highly correlated to its precursor measured
by microarray (supplemental Figure 10), supporting array-based
miR-155 expression assessment. Analysis of these data revealed
differential expression of miR-155 between ABC and GCB-DLBCL
(supplemental Figure 8), consistent with the in-house cohort.
When evaluating the prognostic effect of miR-155 expression,
prognostic stratification was confirmed within the GCB subclass,
with significantly shorter OS and PFS of patients with low levels of
miR-155 (Figure 4). However, miR-155 expression did not provide
prognostic information within the ABC subclass or the entire
cohort. These observations were supported by simple Cox
proportional hazards regression analysis (Table 1), and are in
accordance with the in-house cohort.
In addition, multiple Cox proportional hazards regression analysis
was conducted to test the prognostic value of miR-155 when
combined with other prognostic tools of DLBCL. For multiple Cox
regression analysis, independent variables were only included in the
model if significant results were obtained when performing simple
Cox regression analyses. The analysis revealed that the prognos-
tic value of miR-155 was independent of the well-established
international prognostic index in the GCB subclass, irrespective of
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dichotomized or continuous miR-155 expression (Table 1;
supplemental Table 7). Thus, miR-155 identifies a subgroup with
inferior prognosis among GCB-classified patients. In accordance,
patients with stable or progressive disease at time of response
evaluation43 display lower levels of miR-155 than patients in complete
remission (supplemental Figure 11), supporting the association
between low miR-155 expression and vincristine resistance.
Discussion
In a 2-step strategy, we defined miRNA involvement in vincristine
resistance in DLBCL, first by elucidating the biological role of
miRNAs in vincristine response by functional analysis and second
by evaluating the biomarker potential in 2 independent R-CHOP-
treated DLBCL cohorts. Identification of vincristine response-
specific miRNAs documented miR-155 as highly expressed in
vincristine-sensitive DLBCL cell lines, and functional validation
confirmed a direct link between miR-155 expression and vincristine
response in DLBCL cells. To compensate for cell line-specific
biological effects, analyses were performed in 2 ABC and GCB-
DLBCL cell lines, strengthening the biological interpretation.
Induction of miR-155 increased vincristine sensitivity in GCB cells,
with the strongest phenotype obtained in vincristine-resistant
OCI-Ly7. The endogenous level of miR-155 is relatively low in
OCI-Ly7, supporting significantly increased effect on vincristine
response on induction. Only a complete knockout generated by
indel introduction induced clear cellular resistance in OCI-Ly7,
showing that TuD-155-directed reduction of already low miR-155
levels was not sufficient to cause phenotypic alterations. When
applying similar approaches in ABC cells, no unambiguous asso-
ciation between miR-155 and vincristine response was observed.
However, as a result of high endogenous miR-155 expression in
ABC cells, it may be challenging to further increase miR-155
levels. In GCB cells, in contrast, lentiviral intervention altered the
intracellular level of miR-155 independent of endogenous levels,
suggesting a more stringent and complex regulation of miR-155 in
ABC-DLBCL. Of notice, miR-155 is regulated by a feedback loop
through NF-kB signaling, a pathway reported to be constitutively
active in ABC-DLBCL.44,45
GSEA revealed that ectopic expression of miR-155 affected
G2/M checkpoints and genes involved in mitotic spindle assembly. In
accordance, the cell-cycle checkpoint gene WEE1 was inversely
correlated with miR-155 in exogenously modified GCB-DLBCL
cells, and in addition, induced levels of Wee1 protein were
observed in miR-155 knockout clones. Although Wee1 is an
experimentally verified target of miR-155,41 it has not previously
been validated in DLBCL cells, which is of great importance, as
affected targets vary depending on the cell type in which the
miRNA is expressed.46
A study by Visconti et al.42 reported that the Fcp1-Wee1-Cdk1 axis
controls spindle assembly checkpoints (SAC), which ensures
proper chromosome segregation by delaying mitosis exit until
mitotic spindle assembly.47 Antimicrotubule drugs, including
vincristine, impede mitotic spindle assembly by targeting
microtubules, leading to the activation of SAC and extension of
mitosis, which promotes apoptosis.47,48 Resistance to these
types of drugs has been related to the ability of cancer cells to
slip through the SAC and exit mitosis prematurely, and thereby
resist killing.48,49 Activation of Wee1 stimulates SAC slippage,42
suggesting that increased vincristine resistance mediated by
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Figure 3. Analysis of prognostic effect of miR-155 expression. Kaplan-Meier
plots depicting OS of R-CHOP-treated patients with DLBCL in the in-house
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miR-155 knockout could occur through upregulation of Wee1
and increased Wee1 signaling. However, it is important to emphasize
that this study only addresses miR-155 signaling through Wee1.
miR-155 could mediate vincristine resistance by regulating other
targets as well, yet comprehensive target gene analysis was not
the focus in this study.
Genetic and chemical inhibition of Wee1 strengthens the SAC,
prolongs mitosis, and enhances killing of vincristine-treated acute
lymphoblastic leukemia cells.42,50 In agreement, MK-1775, a chemical
inhibitor of Wee1, boosted the effect of vincristine in GCB-DLBCL
cells in this study. Interestingly, MK-1775 potentiated the cytotoxic
effect of doxorubicin, another vital component of R-CHOP,51
supporting combination therapy of R-CHOP and MK-1775 in
relapsed or refractory DLBCL.
miR-155 is involved in numerous processes that could affect drug
response, including MAPK, PI3K/AKT, and RhoA signaling.52-55 In
line, decreased miR-155 expression in epidermoid carcinoma cells
increased cisplatin resistance by increasing the amount of Wee1
protein,56 similar to the mechanism of miR-155-induced vincristine
resistance reported in this study. Furthermore, suppression of miR-155
was found to reverse doxorubicin resistance in lung cancer cells,
whereas it did not affect the response in DLBCL cells, highlighting
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Figure 4. Analysis of association between OS and PFS and miR-155 expression. Kaplan-Meier plot depicting OS (A-C) and PFS (D-F) of R-CHOP-treated patients
with DLBCL in the meta-cohort, consisting of R-CHOP–restricted Lymphoma/Leukemia Molecular Profiling Project and International DLBCL Rituximab-CHOP Consortium MD
Anderson Project data. Before analysis, data were ComBat normalized to compensate for study-wise batch effect. Analyses were conducted for all patients with DLBCL (A,D),
ABC-classified patients (B,E), and GCB-classified patients (C,F). For each cohort, patients were dichotomized by median split of MIR155HG expression.
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the tissue-specific effect of a particular miRNA.13,57 Whether
miR-155 has an effect on other compounds of R-CHOP is unknown.
However, rituximab exerts its action through CD20, whereas cyclo-
phosphamide has alkylating properties and furthermore induces
cytokine release, leading to antibody-mediated elimination,58 all of
which are mechanisms differing from those of vincristine. Thus,
miR-155 does most likely not affect rituximab and cyclophospha-
mide response through Wee1, but has the potential through other
targets.
To evaluate the prognostic effect of miR-155, expression levels
were analyzed for association with clinical outcome. It is noteworthy
that the clinical outcome is a result of the entire R-CHOP regimen,
and therefore, we investigated the prognostic potential of miR-155
regardless of its association to vincristine response. Investigation of
the meta-cohort demonstrated decreased OS and PFS for
patients with GCB-DLBCL with low MIR155HG expression.
Notably, miR-155 identifies a subgroup of GCB-DLBCL with
inferior clinical outcome comparable to ABC-classified patients.
The beneficial effect of miR-155 on clinical outcome was a
surprising observation when considering the commonly accepted
perception of miR-155 as an oncomiR, yet documenting that the
effect of a particular miRNA is dependent on the cell type in which
it is expressed.
When examining the association between miR-155 and the ABC/
GCB subclasses, it was confirmed that miR-155 is more expressed
in ABC-DLBCL,19 which is in accordance with the role of miR-155
as an oncomiR, as ABC-classified patients have a dismal prognosis.
Furthermore, clinical analysis revealed that miR-155 only dis-
played prognostic value within the GCB subclass, highlighting the
molecular heterogeneity between the 2 molecular subclasses of
DLBCL. These findings, in combination with the different func-
tional effect of miR-155 on vincristine response in ABC and
Table 1. MIR155HG expression is an IPI-independent prognostic marker for R-CHOP-treated patients with GCB-DLBCL
n no.
Simple Multiple
HR 95% CI P HR 95% CI P
All DLBCL
miR-155
Low 293 90 1 —
High 293 107 1.17 0.88-1.54 .28 — — —
IPI
0-1 71 6 1 1
2-3 314 84 3.76 1.64-8.61 .0017 3.42 1.49-7.84 .0038
4-5 201 106 9.61 4.22-21.88 7.19e-08 8.29 3.62-18.98 5.73e-07
Subclass
ABC 242 105 1 1
GCB 248 58 0.45 0.33-0.62 1.09e-06 0.55 0.40-0.76 .00032
UC 96 34 0.73 0.50-1.08 .11 0.71 0.48-1.05 .089
ABC-DLBCL
miR-155
Low 121 57 1 —
High 121 48 0.78 0.53-1.14 .20 — — —
IPI
0-1 15 2 1 —
2-3 125 38 3.57 0.86-14.89 .080 — — —
4-5 102 65 10.37 2.51-42.87 .0012 — — —
GCB-DLBCL
miR-155
Low 124 41 1 1
High 124 17 0.40 0.23-0.71 .0017 0.46 0.26-0.81 .0071
IPI
0-1 48 2 1 1
2-3 140 32 6.22 1.49-25.97 .012 5.91 1.42-24.69 .015
4-5 60 24 12.53 2.96-53.06 .0006 11.10 2.61-47.15 .0011
Array-based miR-155 expression and outcome were analyzed by simple and multiple Cox proportional hazards regression analyses for OS. IPI (international prognostic index) score
information was not available for all patients, thus cohort sizes are reduced in this setting (115 samples were removed). MIR155HG expression was dichotomized by median split in each of
the individual cohorts: all DLBCL patients, ABC-classified patients, and GCB-classified patients.
—, value not available because variables were only included in multiple Cox proportional hazards regression analysis if significant results were obtained in simple Cox proportional hazards
regression analysis; CI, 95% lower and upper confidence intervals; HR, hazard ratio; n, number of samples; no., number of events.
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GCB cells, suggest that miR-155 affects different targets, depend-
ing on the cell of origin.
Contradictory to the beneficial effect of miR-155 observed in this
study, Iqbal et al13 reported high miR-155 expression to be associated
with R-CHOP treatment failure in DLBCL. However, unlike the current
study, patients with DLBCLwere divided according to survival risk and
not miR-155 expression, and furthermore, without subtype-specific
focus. In addition, by dichotomizing patients with DLBCL on miR-155
expression, Zhong et al59 documented inferior prognosis of patients
with DLBCL with high miR-155 levels, whereas no prognostic
stratification was observed in the study of Go et al.60 Yet, to the best
of our knowledge, this is the first prognostic evaluation of miR-155
with a DLBCL subtype-specific focus, thereby taking the different
pathogenesis of the molecular subclasses into consideration.
In conclusion, experimentally, we confirm a direct functional link
between miR-155 expression and vincristine response in DLBCL.
This role is supported by prognostic evaluation in 2 independent
DLBCL cohorts treated with R-CHOP, documenting a significantly
improved clinical outcome of GCB-classified patients with high
miR-155 expression. The data suggest that the role of miR-155 on
vincristine response is important enough to affect OS and PFS of
patients with GCB-DLBCL treated with R-CHOP.
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